Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Research News
back to News Search
Glutamate Receptor Blockers Reverse Fragile X Symptoms in Mice

Adapted from a story that originally appeared on the Alzheimer Research Forum.

17 April 2012. Because neurons are postmitotic—unable to divide or regenerate once formed in the brain—scientists long believed that neurodevelopmental diseases were irreversible. Recent research began to challenge that thinking, and a mouse study in yesterday’s Neuron offers compelling evidence that Fragile X syndrome (FXS)—the most common inherited form of mental retardation—can be reversed well after symptoms have developed. A team led by Lothar Lindemann of Hoffman-La Roche in Basel, Switzerland, and Mark Bear of the Massachusetts Institute of Technology fixed a wide array of defects in adult FXS mice using a compound that blocks the mGlu5 form of metabotropic glutamate receptor. The findings lend hope for mGlu5 agents being tested in ongoing clinical trials of people with Fragile X and related brain disorders.

The study does not have immediate implications for schizophrenia. However, because the disorder is thought by most researchers to have neurodevelopmental origins (for review, see Weinberger, 1996), progress against Fragile X provides hope that the effects of abnormal neurodevelopment might also be reversed in disorders that appear in adolescence. Moreover, glutamate signaling is a major focus for psychosis treatment research (see hypothesis papers by B. Moghaddam and D. Javitt).

Afflicting one in 4,000 boys and about half as many girls, Fragile X syndrome arises from disruptions in a single X-chromosome gene, Fmr1, reducing expression of Fragile X mental retardation protein (FMRP). “Excess” characterizes many Fragile X features—among them excessive excitability, body growth, and synaptic connectivity. Many FXS symptoms have been linked to overactive mGlu5 receptors, which drive synthesis of synaptic proteins. That led Bear to propose that FMRP acts to suppress mGlu5-triggered protein synthesis. According to his theory, mGlu5 activity goes unfettered without FMRP, producing the diverse problems seen in Fragile X (Bear et al., 2004). A genetic study by Bear and colleagues supported this idea—Fmr1 knockout (KO) mice with only one copy of the Grm5 gene and half normal mGlu5 activity were spared a slew of abnormalities seen Fmr1 KO controls (Dölen et al., 2007). While that work established proof of principle that dampening mGlu5 could prevent FX deficits, it did not show that they could be reversed later in life. Other groups improved symptoms in adult mouse and fly Fragile X models using a mGlu5 antagonist (MPEP) (Yan et al., 2005; McBride et al., 2005), but it was only partial relief, and some animals developed tolerance to the compound. The current paper shows “we can intervene pharmacologically after symptom onset and correct many aspects of Fragile X,” Bear told the Alzheimer Research Forum.

Led by co-first authors Aubin Michalon of Roche and Michael Sidorov of MIT, the researchers treated Fmr1 knockout mice with a different mGlu5 blocker, a pyridine derivative called CTEP (Lindemann et al., 2011). Though discovered at Roche, CTEP is not being developed by the company as a human drug, but “has ideal properties for studies in rodents,” Lindemann said. The compound not only has great pharmacokinetics and oral bioavailability, but also is considerably more potent and long-lasting than commercially available mGlu5 inhibitors, for example, MPEP and another Roche compound, fenobam (Porter et al., 2005). In mouse studies, those molecules need to be given four to five times a day because their half-life is a mere hour or two. By comparison, CTEP acts for about 18 hours, allowing researchers to see some symptoms improve in Fmr1 knockout mice after just a single subcutaneous dose (2 mg/kg body weight). For chronic dosing experiments, the mice were given this amount of the inhibitor every other day for four to 17 weeks.

With the exception of macroorchidism (medical speak for enlarged testes), which was only partially rescued, all nine phenotypes analyzed in the study returned to normal with CTEP treatment. Fmr1-deficient mice become startled easily and have trouble acclimating to their environment. They also have problems remembering where danger signals (e.g., foot shocks) are. CTEP rescued these behavioral deficits. Fmr1 knockout mice respond to loud noise with seizures, and have exaggerated hippocampal long-term depression. These, too, were fully corrected by the compound. Moreover, CTEP restored the elevated spine density and protein synthesis rates to normal, and abolished hyperactive ERK kinase and mTOR signaling typically seen in Fmr1 knockouts.

“This article demonstrates that the kind of therapeutic intervention we can realistically implement in patients is extraordinarily effective in reversing the major Fragile X phenotypes at cellular, synaptic, neural circuit, and behavioral levels,” noted Michael Tranfaglia of FRAXA Research Foundation, which funds Fragile X research).

Before the current paper came out, Roche and several other companies had begun developing mGlu5 inhibitors for Fragile X. Roche completed a six-week six-week Phase 2 trial of its compound, R04917523, but results have not been reported. “I am unfortunately unable to disclose data,” Lindemann noted. “We can say, though, that the data obtained so far support continuation of the clinical development of the molecule.” A larger, 12-week Phase 2 study is in the works, with recruitment to begin “any day,” Lindemann said.

Seaside Therapeutics, Inc., of Cambridge, Massachusetts, a company Bear co-founded in 2005, has several Fragile X compounds in its clinical pipeline. One of them—a mGluR antagonist (STX107) licensed from Merck—survived Phase 1 but has languished on the backburner while the company pours resources into another compound—a GABA B receptor agonist (STX209). By ramping up inhibitory activity, this molecule achieves the same effect as mGlu5 blockers—diminished glutamate receptor signaling—but has a faster path to regulatory approval, Bear told Alzforum. It is the active enantiomer of a drug (racemic baclofen) already in use for cerebral palsy and gastroesophageal reflux. The company reported at meetings that the GABA B agonist improved several global measures in an open-label Phase 2 study of autistic patients (see news release). In the Fragile X Phase 2 trial, the compound showed some benefit in participants with severe social avoidance (see news release). Recruitment is underway for a Phase 3 trial of the GABA B agonist in children with Fragile X syndrome.

But the frontrunner may be Novartis’ AFQ056, which has headed into Phase 3 testing. In a Phase 2 trial of 30 men with FXS, the mGlu5 blocker seemed to help a subset of participants with strong Fmr1 gene silencing (Jacquemont et al., 2011).—Esther Landhuis.

Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice. Neuron. 12 April 2012;74:49-56. Abstract

Comments on News and Primary Papers
Comment by:  Bernard Crespi
Submitted 20 April 2012 Posted 25 April 2012
  I recommend the Primary Papers

The emerging possibility of reversing neurodevelopmental...  Read more

View all comments by Bernard Crespi
Submit a Comment on this News Article
Make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory  
*Login Email Address  
*Confirm Email Address  
*Confirm Password  
Remember my Login and Password?  
Get SRF newsletter with recent commentary?  
Enter the code as it is shown below:
This code helps prevent automated registrations.

I recommend the Primary Papers

Please note: A member needs to be both registered and logged in to submit a comment.


(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)


SRF News
SRF Comments
Text Size
Reset Text Size
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright